Johnson & Johnson (JNJ) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Total Revenue Chart for Johnson & Johnson
Johnson & Johnson (JNJ) revenue for FY2025 was USD 94.2B, a 6.0% change from FY2024. Johnson & Johnson's revenue grew from USD 6.4B in 1985 to USD 94.2B in 2025 (1366.9% over 40 years). Earnings per share grew from USD 1.55 in 2000 to USD 11.03 in 2025 (612.4%). Revenue compound annual growth rate: 5-year CAGR of 2.7%, 10-year CAGR of 3.0%, 20-year CAGR of 3.2%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $599.12B
- Implied Share Price
- $248.61
- Enterprise Value
- $677.00B
- Revenue (TTM)
- $97.93B
- EBITDA
- $34.87B
- Profit Margin
- 21.48%
- Trailing P/E
- 28.81
- Forward P/E
- 21.01
- Price/Book (MRQ)
- 7.63
- Price/Sales (TTM)
- 6.12
- EV/EBITDA
- 19.94
- EV/Revenue
- 6.91
- Dividend Yield
- 1.99%
- Book Value
- $35.28
- Free Cash Flow (FY2025)
- $19.70B
- Free Cash Flow Yield
- 3.29%
Snapshot as of 14th October 2026 — not point-in-time controlled, may lag the live market by a few days.